TY - JOUR. T1 - Human C-type natriuretic peptide. AU - Ogawa, Yoshihiro. AU - Nakao, Kazuwa. AU - Nakagawa, Osamu. AU - Komatsu, Yasato. AU - Hosoda, Kiminori. AU - Suga, Shin Ichi. AU - Arai, Hiroshi. AU - Nagata, Kiyoshi. AU - Yoshida, Nobuo. AU - Imura, Hiroo. PY - 1992/6. Y1 - 1992/6. N2 - We isolated the human C-type natriuretic peptide gene and identified the peptide in the brain. The human C-type natriuretic peptide gene appeared to be composed of at least two exons and one intron. In the 5′-flanking region, there is an array of cis elements (an inverted CCA AT box, two GC boxes, and a cyclic AMP response element-like sequence) that is not present in upstream sequences of the atrial and brain natriuretic peptide genes. Analysis of the deduced amino acid sequence revealed that human prepro C-type natriuretic peptide comprises 126 amino acids and that the C-terminal 22-residue peptide (G-L-S-K-G-C-F-G-L-K-L-D-R-I-G-S-M-S-G-L-G-C) preceded by Lys-Lys is identical to the porcine ...
TY - JOUR. T1 - NPR-C receptors are involved in C-type natriuretic peptide response on bile secretion. AU - Sabbatini, Maria E.. AU - Vatta, Marcelo S.. AU - Vescina, Cristina. AU - Gonzales, Soledad. AU - Fernandez, Belisario. AU - Bianciotti, Liliana G.. PY - 2003/11/15. Y1 - 2003/11/15. N2 - C-type natriuretic peptide (CNP) is a member of the natriuretic peptide family. Previous studies reported the presence of natriuretic peptide receptors and mRNA CNP in the liver. In the present work, we sought to establish the role of CNP in the regulation of bile secretion in the rat and the possible pathways involved. CNP diminished basal as well as bile salt-evoked bile flow and bile acid output in a dose-dependent manner. It also reduced the excretion of sodium, chloride, and potassium but did not modify bile pH or the excretion of phospholipids, total proteins, and glutathione. Neither parasympathetic nor sympathetic blockade abolished CNP inhibitory response on bile secretion. The selective NPR-C ...
TY - JOUR. T1 - Regulation of endothelial production of C-type natriuretic peptide by interaction between endothelial cells and macrophages. AU - Suga, Shin Ichi. AU - Itoh, Hiroshi. AU - Komatsu, Yasato. AU - Ishida, Hiroshi. AU - Igaki, Toshio. AU - Yamashita, Jun. AU - Doi, Kentaro. AU - Chun, Tae Hwa. AU - Yoshimasa, Takaaki. AU - Tanaka, Issei. AU - Nakao, Kazuwa. PY - 1998/1/1. Y1 - 1998/1/1. N2 - We demonstrated endothelial production of C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, and its regulation by cytokines, including tumor necrosis factor-α (TNFα). We thus proposed that CNP can control vascular tone and growth as an endothelium-derived relaxing peptide. We also revealed the marked elevation of plasma CNP concentration in patients with septic shock, in which TNFα, plays a significant part. As the interaction between endothelial cells (EC) and monocytes-macrophages plays a pivotal role in the pathogenesis of atherosclerosis, we investigated ...
TY - JOUR. T1 - C-type natriuretic peptide/guanylate cyclase B system in ATDC5 cells, a chondrogenic cell line. AU - Suda, Michio. AU - Tanaka, Kiyoshi. AU - Yasoda, Akihiro. AU - Komatsu, Yasato. AU - Chusho, Hideki. AU - Miura, Masako. AU - Tamura, Naohisa. AU - Ogawa, Yoshihiro. AU - Nakao, Kazuwa. PY - 2002/12/1. Y1 - 2002/12/1. N2 - Natriuretic peptides constitute a family of three structurally related peptides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). Particulate guanylate cyclases, GC-A, and GC-B, are the receptors for these peptides to mediate their action. ANP and BNP possess high affinities for GC-A, and CNP is the preferred ligand for GC-B. In this article, we report our study of the expression and possible role(s) of natriuretic peptides in ATDC5 cells, which represent a chondrogenic cell line. ATDC5 cells produced cyclic guanosine monophosphate (cGMP) in response to natriuretic peptides. CNP was far more potent than ANP ...
TY - JOUR. T1 - Circulating C-Type Natriuretic Peptide and Its Relationship to Cardiovascular Disease in the General Population. AU - Sangaralingham, S. Jeson. AU - McKie, Paul M.. AU - Ichiki, Tomoko. AU - Scott, Christopher G.. AU - Heublein, Denise M.. AU - Chen, Horng H.. AU - Bailey, Kent R.. AU - Redfield, Margaret M.. AU - Rodeheffer, Richard J.. AU - Burnett, John C.. N1 - Publisher Copyright: © 2015 American Heart Association, Inc. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.. PY - 2015/6/20. Y1 - 2015/6/20. N2 - C-type natriuretic peptide (CNP) is an endothelium-derived peptide that is released as a protective mechanism in response cardiovascular injury or disease. However, no studies have investigated circulating CNP, identifying clinical factors that may influence CNP and its relationship to cardiovascular disease in the general population. We studied 1841 randomly selected subjects from Olmsted County, MN (mean age, 63±11 years; 48% men). Plasma CNP was measured ...
C-type natriuretic peptide (CNP) is a member of the natriuretic peptide family and have been implicated to be involved in maintaining vascular homeostasis and acting as a cardiac chronotropic agent in experimental studies. However, clinical evidence of its participation in cardiovascular regulation is lacking, especially in patients with chronic kidney disease (CKD). We aimed to explore the association of circulating CNP with cardiovascular alterations in CKD. Seventy-six subjects with CKD were recruited. Plasma CNP-22, the bioactive form of CNP in the circulation, was measured by an enzyme immunoassay. The patients also underwent several cardiovascular evaluations including measurement of blood pressure, endothelial function, heart rate variability (HRV) and pulse wave velocity. Mean (±standard deviation) age of the patients were 59.9 (±14.9) years and 56.6% were male. Average plasma CNP level was 790.8 ± 309.1 pg/ml. Plasma CNP level was not increased as estimated glomerular filtration rate
Background: Mesangial cell proliferation and matrix accumulation are hallmarks of various progressive glomerular diseases. We examined whether C-type natriuretic peptide (CNP) that is known to regulate the proliferation of vascular smooth muscle cells could modulate these pathological processes using human glomerular mesangial cells (GMCs) in culture. Methods: Proliferation of GMCs cultured with different concentrations of CNP-22 for 48 h was determined by a colorimetric assay using a tetrazorium salt. Monocyte chemoattractant protein-1 (MCP-1) and type IV collagen secretion into the culture media by GMCs in the presence or absence of CNP-22 were evaluated by ELISA. Expression of mRNA for natriuretic peptide receptor B (NPR-B), a specific receptor for CNP, was examined by reverse transcription polymerase chain reaction (RT-PCR). Results: CNP-22 (1-10 µ M ) inhibited serum-induced GMC growth in a dose-dependent manner. The amount of MCP-1 in the culture supernatant was increased approximately 2.4
BACKGROUND: In mammalian follicles, oocytes are arrested at the diplotene stage of prophase I until meiotic resumption following the LH surge. Recently, C-type natriuretic peptide (CNP), encoded by natriuretic peptide precursor type C (NPPC) was found to suppress mouse oocyte maturation by promoting cyclic guanosine 5-monophospate (cGMP) production in cumulus cells. However, regulation of NPPC/CNP expression during the pre-ovulatory period and their regulation by the LH surge have not been investigated.. METHODS AND RESULTS: Based on genome-wide analysis of DNA microarray data sets using samples from periovulatory ovaries, we found increases in NPPC transcripts in granulosa cells during pre-ovulatory follicle growth in mice and a rapid decline induced by the pre-ovulatory LH/hCG stimulation. Treatment of pre-ovulatory animals with hCG decreased ovarian CNP content. In isolated ovarian cells, NPPC mRNA was predominantly expressed in mural granulosa cells exhibiting similar regulation following ...
Natriuretic peptide precursor C, also known as NPPC, is a protein that in humans is encoded by the NPPC gene. The precursor NPPC protein is cleaved to the 22 amino acid peptide C-type natriuretic peptide (CNP). Natriuretic peptides comprise a family of 3 structurally related molecules: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), encoded by a gene symbolized NPPC. These peptides possess potent natriuretic, diuretic, and vasodilating activities and are implicated in body fluid homeostasis and blood pressure control. Unlike ANP and BNP, CNP does not have direct natriuretic activity. This is because CNP is a selective agonist for the B-type natriuretic receptor (NPRB) whereas ANP and BNP are selective for the A-type natriuretic receptor (NPRA). GRCh38: Ensembl release 89: ENSG00000163273 - Ensembl, May 2017 GRCm38: Ensembl release 89: ENSMUSG00000026241 - Ensembl, May 2017 Human PubMed Reference:. Mouse PubMed Reference:. Entrez Gene: ...
Chand, A N and Akbareian, S E and McGonnell, I M and Fowkes, R C (2010) FISH AND CHICKS: C-TYPE NATRIURETIC PEPTIDE AND THE DEVELOPMENT OF THE PITUITARY GLAND IN GALLUS GALLUS AND DANIO RERIO. In: UNSPECIFIED. Full text not available from this repository ...
McNeill, B. A., Wellby, M., Prickett, T. C., Yandle, T. G., Espiner, E. A. and Barrell, G. K. 2009, The fetal cotyledon is a major source of maternal circulating C-type natriuretic peptide in ovine pregnancy, in NZSE/ESA 2009 : Proceedings of the New Zealand Society of Endocrinology / Endocrine Society of Australia 2009 combined meeting, Endocrine Society of Australia, Sydney, N. S. W., pp. 1-1. ...
We have identified recently a new peptide, NT-proCNP(1-50) (N-terminal pro-C-type natriuretic peptide), in the circulation of humans and sheep. A previous report of an elevated fetal-maternal gradient in immunoreactive CNP raised the possibility that processing and metabolism of proCNP may differ in maternal and fetal tissues. We therefore collected matching peripheral maternal and umbilical cord plasma samples at delivery from women with normotensive and pre-eclamptic pregnancies to investigate the presence and concentrations of CNP and NT-proCNP using HPLC and RIA. Plasma concentrations of NT-proCNP in normotensive umbilical cord plasma were 10-fold higher than maternal venous levels (246±17 compared with 24.3±1.8 pmol/l; P,0.001) and much higher than corresponding levels of CNP (3.6±0.4 compared with 1.8±0.3 pmol/l in the fetal and maternal plasma respectively; P,0.001). Although there was no significant difference between normotensive and pre-eclamptic plasma CNP concentrations in either ...
0079]Both the NPR-A and NPR-C (i.e. clearance) receptors were present in these small-cell lung cancer cells. This knowledge helps to explain BNPs and CNPs lack of biologic effects in these cancer cells at their 1-μM concentrations. Atrial natriuretic peptide binds to both the NPR-A and C-receptors with a higher affinity than BNP or CNP. Binding to the NPR-A receptor is ANP,BNP,,CNP while binding to the NPR-C receptor is ANP,CNP,BNP. Binding of human BNP to the human NPRC receptor is an order of magnitude lower than ANP, indicating that an order of magnitude larger concentration of BNP is necessary to be present for BNP to have effects. In the present investigation the inventors have investigated BNP and CNP, which had no effects at 1 μM whereas the other peptide hormones did, at 10-fold and 100-fold higher concentrations. At 10-fold higher (i.e. 10 μM) concentrations of BNP and CNP, neither significantly decreased the number of human small-cell lung cancer cells. Anticancer effects were ...
TY - JOUR. T1 - Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. AU - Potter, Lincoln R.. AU - Abbey-Hosch, Sarah. AU - Dickey, Deborah M.. PY - 2006/2. Y1 - 2006/2. N2 - Natriuretic peptides are a family of structurally related but genetically distinct hormones/paracrine factors that regulate blood volume, blood pressure, ventricular hypertrophy, pulmonary hypertension, fat metabolism, and long bone growth. The mammalian members are atrial natriuretic peptide, B-type natriuretic peptide, C-type natriuretic peptide, and possibly osteocrin/musclin. Three single membrane-spanning natriuretic peptide receptors (NPRs) have been identified. Two, NPR-A/GC-A/NPR1 and NPR-B/GC-B/NPR2, are transmembrane guanylyl cyclases, enzymes that catalyze the synthesis ofcGMP.One, NPR-C/NPR3, lacks intrinsic enzymatic activity and controls the local concentrations of natriuretic peptides through constitutive receptor-mediated internalization and degradation. ...
The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.
The treatment of articular cartilage defects has become a major clinical concern. Currently, additional efforts are necessary to develop effective methods
Figure 1. Brain natriuretic peptide (BNP) is synthesized as a high molecular weight precursor; Biologicaly active form BNP has amino acid sequence 77-108 and the N-terminal proBNP the sequence 1-76. Lower diagram gives the amino acid sequence and 17 amino acid ring structure that is common to all natriuretic peptides.. A third peptide, C-type natriuretic peptide (CNP), a paracrine hormone with high concentrations in the vascular endothelium, belongs to this family as well. There are two forms of CNP consisting of either 53 or 22 amino acids; both lack an amino acid tail at the carboxy terminal.. Another member of the natriuretic peptide family is urodilatin which is localized in the kidneys and secreted into urine. It is a paracrine factor involved in the local regulation of the body fluid volume and water-electrolyte excretion by regulating water and sodium reabsorption. Urodilatin is a differentially processed form of precursor proANP. ANP and CNP are highly conserved across species, whereas ...
We have shown by Boydens chamber method that FCS and PDGF-BB potently stimulate the migration of SMCs. It appears reasonable that FCS induces SMC migration, since blood serum contains numerous growth and migration factors for vascular cells.29 30 Among these factors in serum, PDGF is known to have important roles in the development of atherosclerosis not only as a mitogen but also as a chemoattractant.2 We have confirmed the previous reports3 31 that PDGF-BB, as well as FCS, potently stimulates the migration of SMCs.. Second, we have shown that the natriuretic peptide family, especially CNP, inhibits the migration of SMCs stimulated with FCS and PDGF-BB in a concentration-dependent manner. In addition, when PDGF-BB-induced migration was separated into chemotactic and chemokinetic activities,32 natriuretic peptides strongly suppressed the chemotactic effect of PDGF-BB and modestly suppressed the chemokinetic effect of PDGF-BB. The suppression of the chemotactic effect of PDGF-BB by CNP-22 was ...
Natriuretic Peptides: Peptides that regulate the WATER-ELECTROLYTE BALANCE in the body, also known as natriuretic peptide hormones. Several have been sequenced (ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C-TYPE NATRIURETIC PEPTIDE).
C-type natriuretic peptide (CNP) and its receptor are abundantly distributed in the brain, especially in the arcuate nucleus (ARC) of the hypothalamus associated with regulating energy homeostasis. To elucidate the possible involvement of CNP in energy regulation, we examined the effects of intracerebroventricular administration of CNP on food intake in mice. The intracerebroventricular administration of CNP-22 and CNP-53 significantly suppressed food intake on 4-h refeeding after 48-h fasting. Next, intracerebroventricular administration of CNP-22 and CNP-53 significantly decreased nocturnal food intake. The increment of food intake induced by neuropeptide Y and ghrelin was markedly suppressed by intracerebroventricular administration of CNP-22 and CNP-53. When SHU9119, an antagonist for melanocortin-3 and melanocortin-4 receptors, was coadministered with CNP-53, the suppressive effect of CNP-53 on refeeding after 48-h fasting was significantly attenuated by SHU9119. Immunohistochemical ...
This trial investigated the pharmacokinetic and pharmacodynamic response of plasma Pro C-Type natriuretic peptide (NTproCNP) in children with short stature.
Both sodium nitroprusside (SNP), a nitric oxide (NO) generator, and C-type natriuretic peptide (CNP) have been found to raise cGMP levels in bovine chromaffin cells in a time- and concentration-dependent manner. The effect of these compounds on catecholamine secretion and calcium influx has also been studied, and both compounds were found to produce a slowly developing inhibitory effect on acetylcholine- or depolarization-stimulated catecholamine secretion and calcium increases without affecting the spontaneous release or the basal intracellular Ca2+ concentration. These inhibitory effects were observed only at high doses of acetylcholine or high levels of extracellular potassium and required concentrations of SNP or CNP very similar to those that increased cGMP levels. Preincubation with 100 microM zaprinast, a cGMP-phosphodiesterase inhibitor able to increase cGMP levels, mimicked the inhibitory effects of SNP and CNP. We investigated the effect of the soluble guanylate cyclase inhibitor ...
J:153212 Schmidt H, Stonkute A, Juttner R, Koesling D, Friebe A, Rathjen FG, C-type natriuretic peptide (CNP) is a bifurcation factor for sensory neurons. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16847-52 ...
Kahler, A and McGonnell, I M and Smart, H and Kowalski, A A and Smith, K C and Wathes, D C and Mestre, A M (2020) Fetal morphological features and abnormalities associated with equine early pregnancy loss. Equine Veterinary Journal. ISSN 2042-3306 EL-Magd, M A and Elsayed, S A and El-Shetry, E S and Abdelfattah-Hassan, A and Saleh, A A and Allen, S and McGonnell, I M and Patel, K (2019) The role of chick Ebf genes in the mediolateral patterning of the somites. genesis: The Journal of Genetics and Development. Mirczuk, S M and Lessey, A J and Catterick, A R and Perrett, R M and Scudder, C J and Read, J E and Lipscomb, V J and Niessen, S J M and Childs, A J and McArdle, C A and McGonnell, I M and Fowkes, R C (2019) Regulation and Function of C-Type Natriuretic Peptide (CNP) in Gonadotrope-Derived Cell Lines. Cells, 8 (9). Scudder, C J and Mirczuk, S M and Richardson, K M and Crossley, V J and Regan, J T C and Gostelow, R and Forcada, Y and Hazuchova, K and Harrington, N and McGonnell, I M and ...
Animals. C57BL/6 mice used in this study were purchased from Japan SLC, Inc.. To generate Ostn-transgenic mice, a transgene was designed to express Ostn specifically in the liver under control of the human serum amyloid-P (SAP) component promoter. A 410-bp cDNA corresponding to mouse Ostn coding sequence (GenBank accession no. NM_198112.2) was synthesized with an MfeI restriction site added to the 5′ end and an EcoRI restriction site to the 3′ end. This synthesized mouse Ostn cDNA was inserted into the EcoRI site of the pSG2 vector, which was produced by subcloning of the HindIII-XhoI fragment from pLG1-SAP containing the SAP promoter and rabbit β-globin gene (28) into pBluescript vector, resulting in the SAP-Ostn fusion gene. Next, the NotI-XhoI fragment of the fusion gene (SAP-Ostn transgene, 2.3 kb) was purified and microinjected into the pronucleus of C57BL/6 mouse embryos using standard techniques. Among delivered mice, founders were identified by PCR genotyping with a pair of primers ...
Animals. C57BL/6 mice used in this study were purchased from Japan SLC, Inc.. To generate Ostn-transgenic mice, a transgene was designed to express Ostn specifically in the liver under control of the human serum amyloid-P (SAP) component promoter. A 410-bp cDNA corresponding to mouse Ostn coding sequence (GenBank accession no. NM_198112.2) was synthesized with an MfeI restriction site added to the 5′ end and an EcoRI restriction site to the 3′ end. This synthesized mouse Ostn cDNA was inserted into the EcoRI site of the pSG2 vector, which was produced by subcloning of the HindIII-XhoI fragment from pLG1-SAP containing the SAP promoter and rabbit β-globin gene (28) into pBluescript vector, resulting in the SAP-Ostn fusion gene. Next, the NotI-XhoI fragment of the fusion gene (SAP-Ostn transgene, 2.3 kb) was purified and microinjected into the pronucleus of C57BL/6 mouse embryos using standard techniques. Among delivered mice, founders were identified by PCR genotyping with a pair of primers ...
This gene encodes a member of the TSC22 domain family of leucine zipper transcription factors. The encoded protein is stimulated by transforming growth factor beta, and regulates the transcription of multiple genes including C-type natriuretic peptide. The encoded protein may play a critical role in tumor suppression through the induction of cancer cell apoptosis, and a single nucleotide polymorphism in the promoter of this gene has been associated with diabetic nephropathy. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Aug 2011 ...
ifdef HAVE_CONFIG_H # include elementary_config.h #endif #include ,Elementary.h, #include ,Efreet.h, #include elm_priv.h #ifdef HAVE_MMAN_H # include ,sys/mman.h, #endif //#define DEBUGON 1 #ifdef DEBUGON # define cnp_debug(fmt, args...) fprintf(stderr, __FILE__:%s/%d : fmt , __FUNCTION__, __LINE__, ##args) #else # define cnp_debug(x...) do { } while (0) #endif #define ARRAYINIT(foo) [foo] = // common stuff enum { CNP_ATOM_TARGETS = 0, CNP_ATOM_ATOM, CNP_ATOM_LISTING_ATOMS = CNP_ATOM_ATOM, CNP_ATOM_text_uri, CNP_ATOM_text_urilist, CNP_ATOM_text_x_vcard, CNP_ATOM_image_png, CNP_ATOM_image_jpeg, CNP_ATOM_image_bmp, CNP_ATOM_image_gif, CNP_ATOM_image_tiff, CNP_ATOM_image_svg, CNP_ATOM_image_xpm, CNP_ATOM_image_tga, CNP_ATOM_image_ppm, CNP_ATOM_XELM, // CNP_ATOM_text_html_utf8, // CNP_ATOM_text_html, CNP_ATOM_UTF8STRING, CNP_ATOM_STRING, CNP_ATOM_COMPOUND_TEXT, CNP_ATOM_TEXT, CNP_ATOM_text_plain_utf8, CNP_ATOM_text_plain, CNP_N_ATOMS, }; typedef struct _Tmp_Info Tmp_Info; typedef struct ...
TY - JOUR. T1 - BNP Consensus Panel 2004. T2 - A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.. AU - Silver, Marc A.. AU - Maisel, Alan. AU - Yancy, Clyde W.. AU - McCullough, Peter A.. AU - Burnett, John C.. AU - Francis, Gary S.. AU - Mehra, Mandeep R.. AU - Peacock, William Franklin. AU - Fonarow, Gregg. AU - Gibler, W. Brian. AU - Morrow, David A.. AU - Hollander, Judd. PY - 2004/1/1. Y1 - 2004/1/1. N2 - Among the most exciting developments in the field of heart failure in recent times has been the rediscovery of the natriuretic peptide system and its pleuripotent effects on cardiac structure and function. This is particularly true of its natriuretic and hemodynamic effects. There has been an explosion of the knowledge base seeking to understand the wide range of homeostatic, regulatory, and counter-regulatory functions in which the natriuretic peptide system participates. ...
NPPA [ENSP00000365663]. Cardiodilatin-related peptide; Hormone playing a key role in cardiovascular homeostasis through regulation of natriuresis, diuresis, and vasodilation. Also plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus. Specifically binds and stimulates the cGMP production of the NPR1 receptor. Binds the clearance receptor NPR3; Belongs to the natriuretic peptide family.. Synonyms: NPPA, B0ZBE8, P01160, ANP, B0ZBE8p .... Linkouts: STRING Pharos UniProt OMIM ...
Exercise training results in cardiovascular and metabolic adaptations that may be beneficial in menopausal women by reducing blood pressure, insulin resistance, and cholesterol level. The adaptation of the cardiac hormonal systems oxytocin (OT), natr
NPPB [ENSP00000365651]. Gamma-brain natriuretic peptide; Cardiac hormone which may function as a paracrine antifibrotic factor in the heart. Also plays a key role in cardiovascular homeostasis through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. Specifically binds and stimulates the cGMP production of the NPR1 receptor. Binds the clearance receptor NPR3; Belongs to the natriuretic peptide family.. Synonyms: NPPB, P16860, P16860p, hP16860, 1YK1 .... Linkouts: STRING Pharos UniProt OMIM ...
In der vorliegenden Dissertationsarbeit wurden die kardialen Effekte des C-Typ natriuretischen Peptids (CNP) an wildtypischen Mäusen (Studie 1) und an einem neuen genetischen Mausmodell, mit einer Kardiomyozyten-spezifischen Deletion des Guanylyl-Cyclase B (GC-B) Rezeptors (Studie 2) untersucht. In Studie 1 wurden die Wirkungen von exogenem, synthetischem CNP auf eine durch Druckbelastung-induzierte Herzinsuffizienz in wildtypischen Mäusen (C57Bl6 Hintergrund) untersucht. Dafür wurde CNP parallel zu einer operativen transversen Aortenkonstriktion (TAC) über osmotische Minipumpen in einer Dosierung von 50 ng/kg/min über 14 Tage appliziert. Die 14 Tage TAC führten zu einer ausgeprägten Linksherzhypertrophie. Diese wurde durch exogenes CNP auf zellulärer (verringerte Kardiomyozytenflächen) und molekularer (verringerte BNP mRNA Expression) Ebene signifikant gehemmt. Auch die durch TAC-induzierte linksventrikuläre Dilatation wurde durch exogenes CNP fast vollständig verhindert. Diese ...
Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.. ...
Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.. ...
Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished ...
Natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B), also known as NPR2, is an atrial natriuretic peptide receptor. In humans it is encoded by the NPR2 gene. Atrial natriuretic peptide receptor GRCh38: Ensembl release 89: ENSG00000159899 - Ensembl, May 2017 GRCm38: Ensembl release 89: ENSMUSG00000028469 - Ensembl, May 2017 Human PubMed Reference:. Mouse PubMed Reference:. Entrez Gene: NPR2 natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B). Fox AA, Collard CD, Shernan SK, et al. (2009). Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology. 110 (4): 738-47. doi:10.1097/ALN.0b013e31819c7496. PMC 2735337 . PMID 19326473. Potthast R, Abbey-Hosch SE, Antos LK, et al. (2004). Calcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-B/guanylyl ...
Receptor activator of Nfkb ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis. In turn a neutralizing Ab against RANKL, denosumab improves bone strength in osteoporosis. OPG also improves muscle strength in mouse models of Duchennes muscular dystrophy (mdx) and denervation-induce atrophy, but its role and mechanisms of action on muscle weakness in other conditions remains to be investigated. We investigated the effects of RANKL inhibitors on muscle in osteoporotic women and mice that either overexpress RANKL (HuRANKL-Tg+), or lack Pparb and concomitantly develop sarcopenia (Pparb-/-). In women, denosumab over 3 years improved appendicular lean mass and handgrip strength compared to no treatment, whereas bisphosphonate did not. HuRANKL-Tg+ mice displayed lower limb force and maximal speed, while their leg muscle mass was diminished, with a lower number of type I and II fibers. Both OPG and denosumab increased limb force proportionally to the increase in muscle ...
Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished ...
Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished ...
Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished ...
Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished ...
Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished ...
Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished ...
Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished ...
Receptor for the C-type natriuretic peptide NPPC/CNP hormone. Has guanylate cyclase activity upon binding of its ligand. May play a role in the regulation of skeletal growth.
Background and Objectives: Delirium is a common and major complication subsequent to cardiac surgery. Despite scientific efforts, there are no parameters which reliably predict postoperative delirium. In delirium pathology, natriuretic peptides (NPs) interfere with the blood-brain barrier and thus promote delirium. Therefore, we aimed to assess whether NPs may predict postoperative delirium and long-term outcomes. Materials and Methods: To evaluate the predictive value of NPs for delirium we retrospectively analyzed data from a prospective, randomized study for serum levels of atrial natriuretic peptide (ANP) and the precursor of C-type natriuretic peptide (NT-proCNP) in patients undergoing coronary artery bypass grafting (CABG) with or without cardiopulmonary bypass (off-pump coronary bypass grafting; OPCAB). Delirium was assessed by a validated chart-based method. Long-term outcomes were assessed 10 years after surgery by a telephone interview. Results: The overall incidence of delirium in the ...
Brain Natriuretic Peptide (BNP) injections in adult healthy or infarcted mice led to increased number of non-myocyte cells (NMCs) expressing the nuclear transcription factor Nkx2.5. The aim of this study was to identify the nature of the cells able to respond to BNP as well as the signaling pathway involved. BNP treatment of neonatal mouse NMCs stimulated Sca-1
N2 - *Atrial natriuretic factor (ANP) has shown over recent decades to play an emerging role in the regulation of coronary blood flow as well as systemic blood pressure. The common polymorphism in the atrial natriuretic peptide precursor gene (NPPA), +2238 T/C, was in the previous studies associated with hypertension as well as other cardiovascular conditions. The purpose of the study was to identify the possible relationship between the +2238 T/C polymorphism and restenosis in coronary arteries stented due to the coronary artery disease (CAD ...
Described are the amino acid sequence of natriuretic peptide receptor B (NPRB) and DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.
We analyzed patterning of myocardial AVC differentiation in MZdicer+430 mutant embryos. Nppa (natriuretic peptide precursor type A) is expressed in ventricular and atrial working myocardial cells, whereas bmp4 (bone morphogenetic protein 4) shows a reciprocal expression pattern, restricted to the AVC myocardium. Spatial expression patterns of nppa and bmp4 were unaffected in MZdicer+430 mutants (Online Figure I), demonstrating correct patterning of the myocardium.. Next, we analyzed differentiation of the endocardium. Expression of nfatc1 (nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1) in MZdicer+430 mutant embryos demonstrated the presence of an endocardial lining throughout the heart tube (Online Figure I). Normally, a small population of endocardial cells located at the AVC form ECs, marked by Has2 expression (Figure 1C). Consistent with the increased levels of HA in the cardiac jelly in MZdicer+430 mutants, we found that Has2 expression was no longer restricted to ...
Israeli biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) said Monday that its drug candidate Piclidenoson for the treatment of osteoarthritis in ...
The expression of NPR-A and NPR-B in formalin-fixed human p-CEPI and CEPI-17-CL4 cells by indirect immunofluorescence is shown. A shows a strong expression of N
Nppc - mouse gene knockout kit via CRISPR, 1 kit. |dl||dt|Kit Component:|/dt||dd|- |strong|KN311169G1|/strong|, Nppc gRNA vector 1 in |a href=http://www.origene.com/CRISPR-CAS9/Detail.
Jordyn Cnp, CNP is a General Practice Nurse Practitioner in Mansfield, OH. He is accepting new patients. Be sure to call ahead with Jordyn Cnp to book an appointment.
New Delhi: In a major setback to drugmaker Geltec Private Limited, the Department of Pharmaceuticals (DoP) has junked its review petition against the National Pharmaceutical Pricing Authority (NPPA)...
The drug pricing watchdog stated that few companies still have not submitted the information and that some of them have not submitted the data accordi..